IDH3A and glioblastoma: This is especially relevant given that patients with isocitrate dehydrogenase-mutated glioblastoma have demonstrated significantly longer overall survival and progression-free survival compared to isocitrate dehydrogenase-wildtype cases (overall survival of 39 months vs. 14 months), independent of treatment status [57].